A liposome is a tiny bubble (vesicle), made out of the same material as a cell membrane. Liposomes were first described by British hematologist Dr. Alec. LIPOSOME derives from two Greek words: lipo("fat") and soma ("body"); it is so named because its composition is primarily of phospholipid.

1. Welcome to my
project
Presentation

2. A Study on Development of Liposomal
Drug Delivery of Miconazole Nitrate
Presented by:
Mahbub Alam
ID:201331222005
Department of Pharmacy Bangladesh University

3. Liposome
A liposome is a tiny bubble (vesicle), made out of the same
material as a cell membrane.
Liposomes were first described by British hematologist Dr. Alec.
LIPOSOME derives from two Greek words: lipo("fat") and
soma ("body"); it is so named because its composition is
primarily of phospholipid.

4. Structure of liposome

6. Advantages
 Non-toxic.
Biodegradable.
Lowers systemic toxicity.
Targeted delivery.
Protection of sensitive drug molecules.
Improved pharmacokinetic effects.

7. Disadvantages
Leakage of encapsulated drug during storage.
Short half-life.
Batch to batch variation.
Difficult in large scale manufacturing and sterilization.
Once administered, liposomes can not be removed.

8. Drug Profile: Miconazole
The antifungal agent used topically often in its nitrate
form, to treat candidiasis and other fungal infections.
Structure:
Miconazole Nitrate

9. Mechanism and indication of
Miconazole Nitrate
Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary
to convert lanosterol to ergosterol. As ergosterol is an essential component of the
fungal cell membrane, inhibition of its synthesis results in increased cellular
permeability causing leakage of cellular contents. Miconazole may also inhibit
endogenous respiration, interact with membrane phospholipids, inhibit the
transformation of yeasts to mycelial forms.
Indication
Treatment of skin Nail infection Vaginal infection

10. Methods of Formulation
Ether injection method
Thin film hydration technique
Sonication Method
Reverse Phase Evaporation Technique (REV)

11. Thin film hydration technique
Preparation steps:
Drug + lecithin + cholesterol + solvent
↓
Remove organic solvent at room temperature
↓
Thin layer formed on the walls of flask
↓
Film is rehydrated to form multilamellar liposome

12. Materials used for Formulation
Name of the Ingredient Purpose
Miconazole Nitrate API
Lecithin Vesicle Formation
Cholesterol Vesicle Formation
Chloroform & Methanol Solvent

13. Formulations
Formulation
Code
Drug (mg) Lecithin
(mg)
Cholesterol
(mg)
Ratio Chlorof
orm
(ml)
Methanol
(ml)
Total
(mg)
F1 100 577 323 1:5.7:3.2 37 23 1000
F2 100 635 265 1:6.3:2.6 31 29 1000
F3 100 700 200 1:7:2 25 35 1000
F4 100 760 140 1:7.6:1.4 18 42 1000
F5 100 815 085 1:8.1:0.9 13 47 1000

14. Optimization of Formulation of
Liposomes
 Physical appearance testing can be the most subjective tests performed
on drug substances. The color can be an indication of purity.
 The formulation F3, F4 and F5 are selected by physical appearance
determination.
 The formulation F3, F4, F5 are selected by determination of grittiness.
 The formulation F3, F4, F5 are selected by determination of uniformity
of content of active ingredient.

15. Photographic Visualization Of Miconazole
Nitrate Liposome

16. Entrapment Efficacy
Formulation No Drug : Lecithin :
Cholesterol
Ratio
Percentage
Entrapped Drug
F3 1:7:2 89.74%
F4 1:7.6:1.4 94.41%
F5 1:8.1:0.85 92.92%

17. Results and Discussion
Standard calibration curve data
Concentration (mcg/ml) Absorbance (nm)
2 0.004
4 0.0015
6 0.019
8 0.024
10 0.030

18. Standard calibration curve
y = 0.0031x + 1E-04
R² = 0.966
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0 2 4 6 8 10 12
Series1 Linear (Series1)

19. First order release kinetics of miconazole
nitrate
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Cumulative%drugrelease
Time (min)
Standard F3 F4 F5

20. Higuchi release kinetics of
miconazole nitrate
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9
Cumulative%drugrelease
Square Route of Time (min)
Standard F3 F4 F5

21. Korsmeyer release kinetics of
miconazole nitrate
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
LogCumulative%drugrelease
Log Time (min)
Standard F3 F4 F5

22. Stability analysis of F3, F4, F5 formulation
Properties 1st month 3rd month 6th month
F3 F4 F5 F3 F4 F5
Entrapment
Efficiency
89.74% 94.41% 92.92% 79.55% 93.23% 90.50% Under observation
Grittiness No No No No No No Under observation
Visual aspect Moderate Good Good
Modera
te
Good Good Under observation

23. Conclusion
From the present study, it can be concluded that
Drug release rate and extent were increased.
 To be used efficiently for enhancing absorption.
Ease of application.

24. Thank You